Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AVXL

Anavex Life Sciences Corporation

Sep 12 • 04:00PM ET

9.37

-0.21 -2.19 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ABBV REGN VRTX GILD AMGN MRK LLY PFE BMY

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.57	Insider Own	3.35%	Shs Outstand	85.41M	Perf Week	-0.32%
Market Cap	804.79M	Forward P/E	3.96	EPS next Y	2.37	Insider Trans	0.00%	Shs Float	83.02M	Perf Month	-11.27%
Enterprise Value	703.63M	PEG	-	EPS next Q	-0.14	Inst Own	38.07%	Short Float	30.73%	Perf Quarter	13.99%
Income	-48.17M	P/S	-	EPS this Y	-10.06%	Inst Trans	3.50%	Short Ratio	23.96	Perf Half Y	4.11%
Sales	0.00M	P/B	8.80	EPS next Y	513.86%	ROA	-39.47%	Short Interest	25.51M	Perf YTD	-12.76%
Book/sh	1.06	P/C	7.96	EPS next 5Y	-	ROE	-43.63%	52W High	14.44 -35.11%	Perf Year	87.21%
Cash/sh	1.18	P/FCF	-	EPS past 3/5Y	1.74% 0.85%	ROIC	-52.96%	52W Low	5.03 86.28%	Perf 3Y	-2.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.23% 5.46%	Perf 5Y	146.25%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-13.05%	Oper. Margin	-	ATR (14)	0.60	Perf 10Y	111.04%
Dividend Ex-Date	-	Quick Ratio	8.93	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.30	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.93	EPS Q/Q	-7.34%	SMA20	-1.45%	Beta	0.86	Target Price	34.33
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-10.73%	Rel Volume	0.67	Prev Close	9.58
Employees	42	LT Debt/Eq	0.00	Earnings	Aug 12 BMO	SMA200	-0.52%	Avg Volume	1.06M	Price	9.37
IPO	Aug 02, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	-12.44% -	Trades		Volume	713,758	Change	-2.19%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$16 → $11
Jun-23-22	Initiated	Berenberg	Buy	$40
Sep-23-21	Initiated	BTIG Research	Buy	$35
Dec-16-20	Reiterated	H.C. Wainwright	Buy	$14 → $17
Sep-28-20	Initiated	Ladenburg Thalmann	Buy	$12
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy	$5 → $7
Mar-08-18	Initiated	ROTH Capital	Buy	$6
Feb-13-18	Reiterated	Maxim Group	Buy	$14 → $5
Sep-29-17	Resumed	Noble Financial	Buy	$15
Feb-07-17	Initiated	Noble Financial	Buy	$16
Mar-29-16	Initiated	FBR Capital	Outperform	$10

Show Previous Ratings

Sep-09-25 07:30AM	Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial (GlobeNewswire) +9.73%
Sep-02-25 07:30AM	Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025 (GlobeNewswire)
Aug-26-25 07:30AM	Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine (GlobeNewswire)
Aug-20-25 07:31AM	Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows (Benzinga)
07:30AM	Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease (GlobeNewswire)
01:00PM	Loading…
Aug-13-25 01:00PM	Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-12-25 01:59PM	Anavex Life Sciences: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -5.02%
07:30AM	Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-25 07:30AM	Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 (GlobeNewswire)
Aug-01-25 08:29AM	Anavexs blarcasemine nets win in Phase IIb/III Alzheimers extension study (Clinical Trials Arena)
Jul-31-25 07:31AM	Anavex Life Sciences: Early Blarcamesine Treatment Cuts Alzheimer's Progression by 20 Months (Benzinga)
07:30AM	Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease (GlobeNewswire)
Jul-10-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice (Zacks)
Jul-04-25 09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
May-14-25 05:01PM	Anavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlights: Promising Alzheimer's Data ... (GuruFocus.com)
07:30AM	Loading…
07:30AM	Anavex Life Sciences to Participate at Upcoming Healthcare Conferences (GlobeNewswire)
May-13-25 07:37AM	Anavex Life Sciences: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -5.03%
07:30AM	Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 08:25AM	Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-06-25 07:30AM	Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 (GlobeNewswire) -7.63%
May-01-25 07:30AM	Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX3-71 for the Treatment of Schizophrenia (GlobeNewswire)
Apr-30-25 07:30AM	Anavex Life Sciences to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Apr-23-25 07:30AM	Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board (GlobeNewswire)
Apr-21-25 04:41PM	Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ... (GuruFocus.com) +5.14%
07:30AM	Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East (GlobeNewswire)
Apr-13-25 05:13AM	Anavex: A Small Bit Of Progress Against Alzheimer's Disease (Seeking Alpha)
Apr-11-25 03:00PM	Undercovered Dozen: VICI Properties, General Dynamics, LandBridge, Anavex + (Seeking Alpha)
Apr-07-25 06:31PM	Anavex: Understanding Their Alzheimer's Open-Label Extension Data Skeptically (Seeking Alpha) -8.76%
12:49PM	AD/PD 2025: Long-term data shows Anavexs Blarcamesine benefits in early Alzheimers (Clinical Trials Arena)
12:10PM	Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years (Benzinga)
11:30AM	Loading…
Apr-05-25 11:30AM	Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease (GlobeNewswire)
Mar-31-25 07:30AM	Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Feb-24-25 07:30AM	Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-12-25 07:39AM	Anavex Life Sciences: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Feb-05-25 07:30AM	Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 (GlobeNewswire)
Jan-31-25 08:10AM	Jim Cramer on Anavex Life Sciences Corp. (AVXL): Its A Good Spec (Insider Monkey)
Jan-27-25 07:30AM	Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX 2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio (GlobeNewswire) -6.39%
Jan-15-25 09:00PM	Lightning Round: Sell Viking Therapeutics, says Jim Cramer (CNBC TV) +8.21% -10.41%
07:30AM	Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease (GlobeNewswire)
Jan-13-25 07:30AM	New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients (GlobeNewswire) -6.06%
Jan-06-25 07:30AM	Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.15%
Dec-31-24 09:40AM	Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year? (Zacks)
Dec-30-24 12:00PM	All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy (Zacks) -8.84%
Dec-27-24 06:15AM	Anavex price target raised to $42 from $40 at H.C. Wainwright (TipRanks)
Dec-26-24 01:00AM	Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch and Financial Stability (TipRanks) +15.55%
Dec-24-24 02:00AM	Anavex Life Sciences Corp (AVXL) Q4 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Dec-23-24 11:17PM	Q4 2024 Anavex Life Sciences Corp Earnings Call (Thomson Reuters StreetEvents) +29.55%
07:43AM	Anavex Life Sciences: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease (GlobeNewswire)
Dec-22-24 05:00AM	What To Expect in the Markets This Week (Investopedia)
Dec-16-24 07:30AM	Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 (GlobeNewswire) +8.51%
Dec-09-24 07:30AM	Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference (GlobeNewswire)
Dec-02-24 07:30AM	Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 (GlobeNewswire)
Nov-26-24 07:30AM	Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA (GlobeNewswire)
Nov-25-24 07:30AM	Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal (GlobeNewswire)
Oct-31-24 04:00AM	Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 (GlobeNewswire) +15.94%
Oct-17-24 07:30AM	Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX 3-71 for the Treatment of Schizophrenia (GlobeNewswire)
Oct-09-24 05:01PM	Anavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Sep-03-24 07:30AM	Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 (GlobeNewswire) -9.30%
Aug-06-24 07:48AM	Anavex Life Sciences: Fiscal Q3 Earnings Snapshot (Associated Press Finance) +5.66%
07:30AM	Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 07:30AM	Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 (GlobeNewswire)
Jul-30-24 07:30AM	Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX 2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference (GlobeNewswire) -10.37%
Jul-29-24 08:39AM	Neurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39% (Benzinga)
06:22AM	Anavex seek EMA approval despite shaky pivotal Alzheimers trial data (Clinical Trials Arena)
Jul-28-24 05:00PM	Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference (GlobeNewswire)
Jun-20-24 07:30AM	Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
May-22-24 07:30AM	Anavex Life Sciences Announces Expansion of Leadership Team (GlobeNewswire)
May-15-24 12:00PM	Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-14-24 10:15AM	NASDAQ: AVXL Investor Notice: Update in Lawsuit for Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) announced by the Shareholders Foundation (GlobeNewswire) +8.02%
07:30AM	Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-10-24 11:18AM	Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 07:41AM	Anavex Life Sciences: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
May-02-24 07:30AM	Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 (GlobeNewswire)
Apr-22-24 05:45AM	Anavex Life Sciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL (PR Newswire)
Apr-11-24 07:30AM	Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference (GlobeNewswire)
Mar-31-24 01:46AM	AVXL STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights and Remedies Against Anavex Life Sciences Corporation (Business Wire)
Mar-28-24 01:18PM	Investors in Anavex Life Sciences Corporation Should Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights AVXL (GlobeNewswire)
Mar-25-24 11:55AM	AVXL INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire)
07:30AM	Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-18-24 07:30AM	Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX 3-71 in Schizophrenia (GlobeNewswire) -5.68%
Mar-15-24 05:45AM	Anavex Life Sciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL (PR Newswire)
Mar-04-24 11:46AM	Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire)
Feb-26-24 01:14PM	12 $10 Stocks That Will Triple (Insider Monkey)
07:30AM	Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-08-24 09:39AM	Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript (Insider Monkey)
Feb-07-24 07:43AM	Anavex Life Sciences: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Feb-01-24 07:30AM	Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 (GlobeNewswire)
Jan-31-24 09:55AM	Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade (Zacks) -5.09%
Jan-24-24 12:00PM	Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why (Zacks)
07:30AM	Anavex Life Sciences Reports Publication of ANAVEX 3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX 3-71 in Humans (GlobeNewswire)
Jan-16-24 07:30AM	Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX 3-71 in Schizophrenia (GlobeNewswire)
Jan-12-24 10:10AM	Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire)
Jan-09-24 08:44AM	Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Jan-08-24 07:30AM	Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX 2-73) for Treatment of Neurodevelopmental Disorders (GlobeNewswire) +9.15%
Jan-03-24 12:14PM	Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire) +8.02%

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MISSLING CHRISTOPHER U	President and CEO	Sep 11 '25	Option Exercise	5.04	187,500	945,000	1,655,213	Sep 12 07:00 PM
Thomas Steffen	Director	Jun 05 '25	Option Exercise	1.76	50,000	88,000	55,000	Jun 09 05:30 PM
MISSLING CHRISTOPHER U	President and CEO	Mar 24 '25	Option Exercise	0.92	500,000	460,000	1,750,210	Mar 26 09:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVXL

Anavex Life Sciences Corporation

Upgrade your FINVIZ experience